Media » Laura Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary, AbbVie

Laura Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary, AbbVie

Central to our vision at AbbVie is developing therapies, such as our pan-genotypic HCV treatment, for the most serious diseases and providing access to those treatments. We are pleased to have reached today’s agreement [Licence agreement on hepatitis C treatment glecaprevir/pibrentasvir] with the MPP.

Laura Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary, AbbVie
This website uses cookies to ensure you get the best experience on our website. Learn More